The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 15, 2012
Filed:
Jul. 06, 2011
Werner Breitenstein, Basel, CH;
Takeru Ehara, Cambridge, MA (US);
Claus Ehrhardt, Basel, CH;
Philipp Grosche, Basel, CH;
Yuko Hitomi, Tsukuba, JP;
Yuki Iwaki, Cambridge, MA (US);
Takanori Kanazawa, Tokyo, JP;
Kazuhide Konishi, Tsukuba, JP;
Juergen Klaus Maibaum, Basel, CH;
Keiichi Masuya, Basel, CH;
Atsuko Iwasaki, Tsukuba, JP;
Nils Ostermann, Basel, CH;
Masaki Suzuki, Tsukuba, JP;
Atsushi Toyao, Tsukuba, JP;
Fumiaki Yokokawa, Chromos, SG;
Werner Breitenstein, Basel, CH;
Takeru Ehara, Cambridge, MA (US);
Claus Ehrhardt, Basel, CH;
Philipp Grosche, Basel, CH;
Yuko Hitomi, Tsukuba, JP;
Yuki Iwaki, Cambridge, MA (US);
Takanori Kanazawa, Tokyo, JP;
Kazuhide Konishi, Tsukuba, JP;
Juergen Klaus Maibaum, Basel, CH;
Keiichi Masuya, Basel, CH;
Atsuko Iwasaki, Tsukuba, JP;
Nils Ostermann, Basel, CH;
Masaki Suzuki, Tsukuba, JP;
Atsushi Toyao, Tsukuba, JP;
Fumiaki Yokokawa, Chromos, SG;
Novartis AG, Basel, CH;
Abstract
3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.